Quote:

---

I can't be sure there is a connection, but it would make sense for them to be using data about Leronlimab's ability to ameliorate "severe Covid-19 manifestations" from our Brazilian trial.

---

Yeah sure. They use data from a randomized, double blinded trial which was by far not completed or ready for interim analysis for a report dated Feb. 10th. (we had roughly 30 patients of the 612 patients enrolled in the beginning of January).